Delivery Order SPE2DB20D3101-SPE2DB25FRWB5
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $12,446.64 to AmerisourceBergen Drug Corp for RINVOQ ER 15 mg tablets (30-count units) on September 8, 2025, with completion scheduled for September 9, 2025. This firm fixed-price delivery order represents a non-set-aside competitive award to the pharmaceutical distributor's Corporate Office located in Conshohocken, Pennsylvania. The delivery order falls under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA...
- The Defense Logistics Agency awarded a $197,052.56 firm fixed-price delivery order to AmerisourceBergen Drug Corp on September 17, 2025, for RINVOQ ER 15 mg tablets (30-count units). This is a non-set-aside competitive award with an ultimate completion date of September 18, 2025, to be performed at the vendor's corporate office location in Conshohocken, Pennsylvania. The delivery order is issued under AmerisourceBergen's existing Indefinite Delivery Contract (IDC) with DLA Troop Support Medical,...
- The Defense Logistics Agency awarded a $32,318.92 firm fixed price delivery order to AmerisourceBergen Drug Corp for RINVOQ ER 15 mg tablets (30-count units) on August 1, 2025, with an ultimate completion date of August 4, 2025. This non-competitive delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. The product will be performed at...
- The Defense Logistics Agency awarded a delivery order valued at approximately $40.2K to AmerisourceBergen Drug Corp for RINVOQ ER 15 mg tablets (30-count units) on September 3, 2025, with completion scheduled for September 4, 2025. This firm fixed-price delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (valued at $1 billion through December 2026), which serves as a comprehensive pharmaceutical supply vehicle...
- The Defense Logistics Agency awarded a delivery order valued at $9,728.70 to AmerisourceBergen Drug Corp for RINVOQ ER 30 mg tablets (30-count units) on August 28, 2025, with an ultimate completion date of August 29, 2025. This firm fixed-price delivery order represents a competitively awarded, non-set-aside contract with performance in Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate headquarters. The delivery order is issued under AmerisourceBergen's larger...
- The Defense Logistics Agency awarded a delivery order valued at $37,112.83 to AmerisourceBergen Drug Corp for RINVOQ ER 45 mg tablets (28-tablet units) on July 21, 2025, with an ultimate completion date of July 22, 2025. This firm fixed-price, non-set-aside delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX and valued at $999,999,999.00 through December 2026. The contract is being...
- The Defense Logistics Agency awarded a delivery order valued at $37,029.83 to AmerisourceBergen Drug Corp for RINVOQ ER 30 mg tablets (30-count units) on May 30, 2025, with an ultimate completion date of June 2, 2025. This competitively awarded, non-set-aside contract employs firm fixed pricing and is being fulfilled at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery...
- The Defense Logistics Agency awarded a $30,275.00 firm fixed-price delivery order to AmerisourceBergen Drug Corp for RINVOQ ER 15 mg tablets (30-count units) on August 15, 2025, with an ultimate completion date of August 18, 2025. This non-set-aside competitive award represents a child delivery order under AmerisourceBergen's substantial Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. The order will be performed...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 19, 2025, for the supply of RINVOQ ER 15 mg tablets in quantities of 30-count units. This $52,783.91 firm fixed-price contract represents a non-set-aside competitive award with an ultimate completion date of September 22, 2025. The product will be delivered to AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger...
- The Defense Logistics Agency awarded a delivery order valued at $6,665.61 to AmerisourceBergen Drug Corp for RINVOQ ER 15 mg tablets (30-count units) with a firm fixed price structure. The contract was competitively awarded without a set-aside designation and is scheduled for ultimate completion by June 20, 2025. This delivery order is placed under AmerisourceBergen's existing Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), a $999.99 billion comprehensive...
- SPE2DB20D3101Indefinite Delivery Contract
- SPE2DB20D3101-SPE2DB25FRWB5Delivery Order
The Defense Logistics Agency awarded a delivery order valued at $217,620.97 to AmerisourceBergen Drug Corp for RINVOQ ER 15 mg tablets (30-count units) on September 22, 2025, with completion scheduled for September 23, 2025. This firm fixed-price contract represents a competitively awarded, non-set-aside delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a $1 billion comprehensive pharmaceutical supply vehicle running through December 2026. The product will be performed at the company's corporate office in Conshohocken, Pennsylvania. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Pennsylvania, serves as a critical vendor for federal military and veteran healthcare systems through its extensive portfolio of pharmaceutical products and medical supplies. This delivery order for RINVOQ, a specialty medication, exemplifies the company's role in supporting the Defense Health Agency and other federal healthcare programs with both brand-name and generic medications across multiple therapeutic domains. The company's established track record of fulfilling federal procurement requirements through competitive awards demonstrates its capability to meet the precise medical supply needs of the Department of Defense and its affiliated healthcare organizations.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $217.6k | 9/22/25 |